Praxis Precision Medicines 

Yahoo Finance • 10 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • 27 days ago

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Praxis and would like to discus... Full story

Yahoo Finance • last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX).  Such investors are advised to contact Danielle Pe... Full story

Yahoo Finance • last month

Praxis Precision Medicines to Participate in September Investor Conferences

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS)... Full story

Yahoo Finance • last month

Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (NASDAQ:PRAX), Align Technology, In... Full story

Yahoo Finance • last month

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • 2 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its partici... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX).  Such investors are advised to contact Danielle Peyt... Full story

Yahoo Finance • 2 months ago

Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock

Investing.com - Piper Sandler has reiterated an Overweight rating and $270.00 price target on Praxis Precision Medicines Inc . (NASDAQ:PRAX), currently trading at $45.94, following positive Phase 2 RADIANT FOS data. According to Investing... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyt... Full story

Yahoo Finance • 2 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Praxis Precision Medicines, Inc. (“Praxis” or “the Company”) (NASDAQ:... Full story

Yahoo Finance • 2 months ago

Praxis Precision Medicines stock price target raised by Wedbush to $33

Investing.com - Wedbush raised its price target on Praxis Precision Medicines Inc . (NASDAQ:PRAX) to $33.00 from $28.00 on Monday, while maintaining an Underperform rating on the stock. According to InvestingPro data, PRAX’s stock has sho... Full story

Yahoo Finance • 2 months ago

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset... Full story

Yahoo Finance • 2 months ago

Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine

PRAXIS PRECISION MEDICINES (NASDAQ:PRAX) REPORTS Q2 2025 RESULTS AMID POSITIVE CLINICAL TRIAL DATA Praxis Precision Medicines (NASDAQ:PRAX [https://www.chartmill.com/stock/quote/PRAX]) reported its second-quarter 2025 financial results al... Full story

Yahoo Finance • 2 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational... Full story

Yahoo Finance • 3 months ago

Praxis Precision gets FDA breakthrough therapy status for Relutrigine

[Brain model with neuron and receptor] dem10/iStock via Getty Images * Praxis Precision Medicines (NASDAQ:PRAX [https://seekingalpha.com/symbol/PRAX]) said that the U.S. FDA has given breakthrough therapy status to Relutrigine, a treatm... Full story

Yahoo Finance • 3 months ago

Notable Wednesday Option Activity: DRI, PRAX, TGTX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Darden Restaurants, Inc. (Symbol: DRI), where a total volume of 7,290 contracts has been traded thus far today, a contrac... Full story

Yahoo Finance • 3 months ago

Prax Group, Owner of Lindsey Oil Refinery, Enters Insolvency - report

Investing.com -- Prax Group, the owner of the Lindsey oil refinery in Lincolnshire, has entered insolvency proceedings, putting hundreds of jobs at risk, according to Sky News report on Monday. State Oil, the parent company of Prax Group,... Full story

Yahoo Finance • 6 months ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story

Yahoo Finance • 6 months ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story